




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 43/00, A61K 31/55	A1	(11) International Publication Number: WO 00/42849 (43) International Publication Date: 27 July 2000 (27.07.00)
<p>(21) International Application Number: PCT/US99/30424</p> <p>(22) International Filing Date: 21 December 1999 (21.12.99)</p> <p>(30) Priority Data: 60/116,647 21 January 1999 (21.01.99) US</p> <p>(71) Applicant: BRISTOL-MYERS SQUIBB CO. [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).</p> <p>(72) Inventors: RAGHIVAN, Krishnaswamy, S.; 3 Hickory Court, Cranbury, NJ 08512 (US). MALLOY, Timothy, M.; 121 W. 5th Street, Bridgeport, PA 19405 (US). VARIA, Sailesh, A.; 10 Clarendon Court, Princeton Junction, NJ 08550 (US).</p> <p>(74) Agents: MARENBERG, Barry, J. et al.; Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543-4000 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <div data-bbox="1050 952 1289 1019" data-label="Image"> </div> <p>*G00001*</p>

(54) Title: COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7- β -CYCLODEXTRIN OR 2-HYDROXYPROPYL- β -CYCLODEXTRIN AND METHOD

(57) Abstract

A ras-farnesyltransferase inhibitor complex formed of ras-farnesyltransferase inhibitor or a pharmaceutically acceptable salt thereof, of formula (I), wherein n is 0 or 1; R₁ is selected from Cl, Br, phenyl, pyridyl or cyano; R₂ is aralkyl; R₃ is selected from lower alkyl, aryl or substituted aryl or heterocyclo; Z₁ is selected from CO, SO₂, CO₂ or SO₂NR₅, R₅ is selected from hydrogen, lower alkyl or substituted alkyl; and sulfobutylether-7- β -cyclodextrin or 2-hydroxypropyl- β -cyclodextrin is provided. The complex has unexpectedly high aqueous solubility of the ras-farnesyltransferase inhibitor and is useful for its intravenous delivery to humans with cancer. Also provided is a method for forming the complex. The ras-farnesyltransferase inhibitors are useful as anti-tumor agents.



(I)



162162